Zobrazeno 1 - 10
of 479
pro vyhledávání: '"Richard A, Koup"'
Autor:
Myra Happe, Amelia R. Hofstetter, Jing Wang, Galina V. Yamshchikov, LaSonji A. Holman, Laura Novik, Larisa Strom, Francis Kiweewa, Salim Wakabi, Monica Millard, Colleen F. Kelley, Sarah Kabbani, Srilatha Edupuganti, Allison Beck, Florence Kaltovich, Tamar Murray, Susanna Tsukerman, Derick Carr, Carl Ashman, Daphne A. Stanley, Aurélie Ploquin, Robert T. Bailer, Richard Schwartz, Fatim Cham, Allan Tindikahwa, Zonghui Hu, Ingelise J. Gordon, Nadine Rouphael, Katherine V. Houser, Emily E. Coates, Barney S. Graham, Richard A. Koup, John R. Mascola, Nancy J. Sullivan, Merlin L. Robb, Julie A. Ake, Kirsten E. Lyke, Mark J. Mulligan, Julie E. Ledgerwood, Hannah Kibuuka, the VRC 208 and RV 422 study team
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-11 (2024)
Abstract Ebola virus disease (EVD) is a filoviral infection caused by virus species of the Ebolavirus genus including Zaire ebolavirus (EBOV) and Sudan ebolavirus (SUDV). We investigated the safety and immunogenicity of a heterologous prime-boost reg
Externí odkaz:
https://doaj.org/article/a738fdd17f884be498b68c55cc2e29cd
Autor:
Allan C. deCamp, Martin M. Corcoran, William J. Fulp, Jordan R. Willis, Christopher A. Cottrell, Daniel L. V. Bader, Oleksandr Kalyuzhniy, David J. Leggat, Kristen W. Cohen, Ollivier Hyrien, Sergey Menis, Greg Finak, Lamar Ballweber-Fleming, Abhinaya Srikanth, Jason R. Plyler, Farhad Rahaman, Angela Lombardo, Vincent Philiponis, Rachael E. Whaley, Aaron Seese, Joshua Brand, Alexis M. Ruppel, Wesley Hoyland, Celia R. Mahoney, Alberto Cagigi, Alison Taylor, David M. Brown, David R. Ambrozak, Troy Sincomb, Tina-Marie Mullen, Janine Maenza, Orpheus Kolokythas, Nadia Khati, Jeffrey Bethony, Mario Roederer, David Diemert, Richard A. Koup, Dagna S. Laufer, Juliana M. McElrath, Adrian B. McDermott, Gunilla B. Karlsson Hedestam, William R. Schief
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-13 (2024)
Abstract Vaccine priming immunogens that activate germline precursors for broadly neutralizing antibodies (bnAbs) have promise for development of precision vaccines against major human pathogens. In a clinical trial of the eOD-GT8 60mer germline-targ
Externí odkaz:
https://doaj.org/article/2e580eabca0b4c0f8e97acb243086a89
Autor:
Chaim A. Schramm, Damee Moon, Lowrey Peyton, Noemia S. Lima, Christian Wake, Kristin L. Boswell, Amy R. Henry, Farida Laboune, David Ambrozak, Samuel W. Darko, I-Ting Teng, Kathryn E. Foulds, Andrea Carfi, Darin K. Edwards, Peter D. Kwong, Richard A. Koup, Robert A. Seder, Daniel C. Douek
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-17 (2023)
Abstract As SARS-CoV-2 variants continue evolving, testing updated vaccines in non-human primates remains important for guiding human clinical practice. To date, such studies have focused on antibody titers and antigen-specific B and T cell frequenci
Externí odkaz:
https://doaj.org/article/5c17ee640e21465b8f13ef277281b87f
Autor:
Yunda Huang, Lily Zhang, Shelly Karuna, Philip Andrew, Michal Juraska, Joshua A. Weiner, Heather Angier, Evgenii Morgan, Yasmin Azzam, Edith Swann, Srilatha Edupuganti, Nyaradzo M. Mgodi, Margaret E. Ackerman, Deborah Donnell, Lucio Gama, Peter L. Anderson, Richard A. Koup, John Hural, Myron S. Cohen, Lawrence Corey, M. Juliana McElrath, Peter B. Gilbert, Maria P. Lemos
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-19 (2023)
Abstract Broadly neutralizing monoclonal antibodies (mAbs) are being developed for HIV-1 prevention. Hence, these mAbs and licensed oral pre-exposure prophylaxis (PrEP) (tenofovir-emtricitabine) can be concomitantly administered in clinical trials. I
Externí odkaz:
https://doaj.org/article/1573cc55a90c4367a36a05f7470f768e
Autor:
Hongying Duan, Angela R. Corrigan, Cheng Cheng, Andrea Biju, Christopher A. Gonelli, Adam S. Olia, I-Ting Teng, Kai Xu, Sijy O’Dell, Sandeep Narpala, Mike Castro, Leonid Serebryannyy, Jennifer Wang, Danealle K. Parchment, Edward K. Sarfo, Jelle van Schooten, John-Paul Todd, Shuishu Wang, Darcy R. Harris, Hui Geng, Alexander J. Jafari, Ruth A. Woodward, Nicole A. Doria-Rose, Kathryn E. Foulds, Adrian B. McDermott, Marit J. van Gils, Richard A. Koup, Theodore C. Pierson, Peter D. Kwong, John R. Mascola
Publikováno v:
iScience, Vol 27, Iss 2, Pp 108877- (2024)
Summary: Soluble ‘SOSIP’-stabilized HIV-1 envelope glycoprotein (Env) trimers elicit dominant antibody responses targeting their glycan-free base regions, potentially diminishing neutralizing responses. Previously, using a nonhuman primate model,
Externí odkaz:
https://doaj.org/article/bc8aa3b518694807a3c5228e93d29f17
Autor:
Cuiping Liu, Lingshu Wang, Jonah S. Merriam, Wei Shi, Eun Sung Yang, Yi Zhang, Man Chen, Wing-Pui Kong, Cheng Cheng, Yaroslav Tsybovsky, Tyler Stephens, Raffaello Verardi, Kwanyee Leung, Cody Stein, Adam S. Olia, Darcy R. Harris, Misook Choe, Baoshan Zhang, Barney S. Graham, Peter D. Kwong, Richard A. Koup, Amarendra Pegu, John R. Mascola
Publikováno v:
npj Vaccines, Vol 8, Iss 1, Pp 1-10 (2023)
Abstract While several COVID-19 vaccines have been in use, more effective and durable vaccines are needed to combat the ongoing COVID-19 pandemic. Here, we report highly immunogenic self-assembling SARS-CoV-2 spike-HBsAg nanoparticles displaying a si
Externí odkaz:
https://doaj.org/article/9b37253d44914adeb9ec845f4062bcd4
Autor:
Wanwisa Promsote, Ling Xu, Jason Hataye, Giulia Fabozzi, Kylie March, Cassandra G. Almasri, Megan E. DeMouth, Sarah E. Lovelace, Chloe Adrienna Talana, Nicole A. Doria-Rose, Krisha McKee, Sabrina Helmold Hait, Joseph P. Casazza, David Ambrozak, Jochen Beninga, Ercole Rao, Norbert Furtmann, Joerg Birkenfeld, Elizabeth McCarthy, John-Paul Todd, Constantinos Petrovas, Mark Connors, Andrew T. Hebert, Jeremy Beck, Junqing Shen, Bailin Zhang, Mikhail Levit, Ronnie R. Wei, Zhi-yong Yang, Amarendra Pegu, John R. Mascola, Gary J. Nabel, Richard A. Koup
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-13 (2023)
Abstract Agents that can simultaneously activate latent HIV, increase immune activation and enhance the killing of latently-infected cells represent promising approaches for HIV cure. Here, we develop and evaluate a trispecific antibody (Ab), N6/αCD
Externí odkaz:
https://doaj.org/article/8e5eb98b4e8744a192139410ac1ac511
Autor:
Ahmed S. Fahad, Cheng Yu Chung, Sheila N. López Acevedo, Nicoleen Boyle, Bharat Madan, Matías F. Gutiérrez-González, Rodrigo Matus-Nicodemos, Amy D. Laflin, Rukmini R. Ladi, John Zhou, Jacy Wolfe, Sian Llewellyn-Lacey, Richard A. Koup, Daniel C. Douek, Henry H. Balfour, David A. Price, Brandon J. DeKosky
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Adoptive immune therapies based on the transfer of antigen-specific T cells have been used successfully to treat various cancers and viral infections, but improved techniques are needed to identify optimally protective human T cell receptors
Externí odkaz:
https://doaj.org/article/eeee0fb53a204636b7baa68d6140de84
Autor:
Bryan T. Mayer, Lily Zhang, Allan C. deCamp, Chenchen Yu, Alicia Sato, Heather Angier, Kelly E. Seaton, Nicole Yates, Julie E. Ledgerwood, Kenneth Mayer, Marina Caskey, Michel Nussenzweig, Kathryn Stephenson, Boris Julg, Dan H. Barouch, Magdalena E. Sobieszczyk, Srilatha Edupuganti, Colleen F. Kelley, M. Juliana McElrath, Huub C. Gelderblom, Michael Pensiero, Adrian McDermott, Lucio Gama, Richard A. Koup, Peter B. Gilbert, Myron S. Cohen, Lawrence Corey, Ollivier Hyrien, Georgia D. Tomaras, Yunda Huang
Publikováno v:
Pharmaceutics, Vol 16, Iss 5, p 594 (2024)
Monoclonal antibodies are commonly engineered with an introduction of Met428Leu and Asn434Ser, known as the LS mutation, in the fragment crystallizable region to improve pharmacokinetic profiles. The LS mutation delays antibody clearance by enhancing
Externí odkaz:
https://doaj.org/article/34ca5d472d9b40e7a742cd8a83e9c15b
Autor:
David Benkeser, Youyi Fong, Holly E. Janes, Elizabeth J. Kelly, Ian Hirsch, Stephanie Sproule, Ann Marie Stanley, Jill Maaske, Tonya Villafana, Christopher R. Houchens, Karen Martins, Lakshmi Jayashankar, Flora Castellino, Victor Ayala, Christos J. Petropoulos, Andrew Leith, Deanne Haugaard, Bill Webb, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Lars W. P. van der Laan, Nima S. Hejazi, Lindsay N. Carpp, April K. Randhawa, Michele P. Andrasik, James G. Kublin, Margaret Brewinski Isaacs, Mamodikoe Makhene, Tina Tong, Merlin L. Robb, Lawrence Corey, Kathleen M. Neuzil, Dean Follmann, Corey Hoffman, Ann R. Falsey, Magdalena Sobieszczyk, Richard A. Koup, Ruben O. Donis, Peter B. Gilbert, on behalf of the AstraZeneca AZD1222 Clinical Study Group, the Immune Assays Team, the United States Government (USG)/CoVPN Biostatistics Team
Publikováno v:
npj Vaccines, Vol 8, Iss 1, Pp 1-13 (2023)
Abstract In the phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine conducted in the U.S., Chile, and Peru, anti-spike binding IgG concentration (spike IgG) and pseudovirus 50% neutralizing antibody titer (nAb ID50) measured four weeks after two d
Externí odkaz:
https://doaj.org/article/4081698c1e354ea79e55b3bd26cbe811